發(fā)布時間：2018-02-25 23:35

  本文關(guān)鍵詞： 老年 輔助治療 膠質(zhì)母細胞瘤 預(yù)后　出處：《廣東醫(yī)學(xué)》2017年01期 　論文類型：期刊論文

【摘要】：目的探討短程放療聯(lián)合替莫唑胺(TMZ)方案在術(shù)后KPS評分較差的老年膠質(zhì)母細胞瘤(GBM)患者治療中的生存獲益情況。方法回顧分析行完整切除但術(shù)后KPS評分不佳的新診斷老年GBM患者71例,對不同MGMT狀態(tài)下各輔助治療方案進行生存分析和比較。結(jié)果 71例患者年齡65~85歲,平均(71.10±5.19)歲,其中男50例,年齡(71.36±5.35)歲,女21例,年齡(70.48±4.90)歲;其中62例在隨訪截止日期前死亡,總體平均生存期(OS)(11.92±0.51)個月,2年生存率0;接受短程同步放化療聯(lián)合TMZ輔助治療組平均生存期顯著提高(P=0.002),與單純短程放療組相比差異性最大(P=0.001),而單純短程放療與單純TMZ輔助治療組之間OS差異無統(tǒng)計學(xué)意義(P0.05);術(shù)后免疫組化MGMT陰性表達組患者更能從短程同步放化療聯(lián)合TMZ輔助化療中獲得生存獲益(P=0.004)。結(jié)論對于≥65歲接受腫瘤切除后功能狀態(tài)不佳的老年GBM患者,短程同步放化療聯(lián)合TMZ輔助治療可能是一種能獲得更多生存獲益的術(shù)后輔助治療方案,在MGMT啟動子甲基化患者中,這種獲益優(yōu)勢更加明顯。
[Abstract]:Objective to investigate the survival benefits of short-course radiotherapy combined with temozolidomide in the treatment of elderly patients with glioblastoma with poor KPS score after operation. Methods New diagnosis with complete resection but poor postoperative KPS score was retrospectively analyzed. 71 elderly patients with GBM, Results 71 patients (50 males, 71.36 鹵5.35) and 21 females (70.48 鹵4.90) years old died before the deadline of follow-up, and 71 patients were 65 ~ 85 years old with an average age of 71.10 鹵5.19 years, including 50 males (71.36 鹵5.35) years old and 21 females (70.48 鹵4.90) years old. The overall mean survival time was 11.92 鹵0.51 months and the 2-year survival rate was 0. The mean survival time of the patients receiving short course radiotherapy and chemotherapy combined with TMZ adjuvant therapy was significantly higher than that of the simple short course radiotherapy group, and the difference was greatest compared with that of the simple short course radiotherapy group, while that of the simple short course radiotherapy group was higher than that of the simple TMZ group. There was no significant difference in OS between adjuvant treatment groups (P 0.05), and the survival benefit of patients with negative expression of immunohistochemical MGMT was more likely to be obtained from short course simultaneous radiotherapy and chemotherapy combined with TMZ adjuvant chemotherapy. Conclusion for patients 鈮，

本文編號：1535651